воскресенье, 19 июня 2016 г.

Morgan Stanley Reaffirms "Hold" Rating for Keryx Biopharmaceuticals

Morgan Stanley Reaffirms "Hold" Rating for Keryx Biopharmaceuticals


's stock had its "hold" rating reaffirmed by equities researchers at Morgan Stanley in a note issued to investors on Saturday. Shares of Keryx Biopharmaceuticals traded up 0.83% during midday trading on Friday, hitting $6.05.



from Biotech News